Island boosts Galidesivir supply as Ebola surges

• Island commissions additional Galidesivir production with PI Health Sciences
• Expected to have 700-800 treatment courses by Q4 CY26
• Expanded inventory to support active outbreak response and biodefence
• Bundibugyo Ebola outbreak spreading rapidly across Central Africa
• Galidesivir expected to be deployed in Uganda during CY26

Island Pharmaceuticals Ltd (ASX: ILA) has commissioned an additional manufacturing campaign of GMP-grade Galidesivir with PI Health Sciences to significantly increase its available supply. Upon completion, expected in Q4 CY26, Island will have approximately 700-800 treatment courses of Galidesivir. This expanded inventory aims to support active outbreak response, biodefence opportunities, and government engagement. The decision follows the ongoing Bundibugyo Ebola outbreak in Central Africa, which has reported 5,208 confirmed cases and 2,476 deaths as of 18 August 2026. Galidesivir, which has shown strong efficacy in non-human primate models for multiple filoviruses, is expected to be deployed in Uganda during CY26, providing an opportunity to generate human efficacy, safety, and virological data.

Expected to have 700-800 treatment courses of Galidesivir by Q4 CY26

Island aims to strengthen its position as a broad-spectrum antiviral and biodefence countermeasure with expanded Galidesivir inventory.